Ultime notizie per Oscar Health (NYSE:OSCR) Azioni

Oscar Health

Oscar Health Inc is a health insurance company. The company provides various insurance plans for individuals, families, and employees. Also, the company provides virtual care, doctor support, scheduling appointments, and other related services. The company provides plans in the Medicare Advantage program to adults who are age 65 and older and eligible for traditional Medicare but who instead select coverage through a private market plan.

Market, Stock, Trading, Stocks, Markets shutterstock_2283804651

Equities

OSCR

Un&#39;azienda vede le sue azioni volare con guadagni impressionanti. Segnali cruciali indicano un potenziale di crescita ancora da esplorare.

Questo titolo è salito del 30% in 5 giorni e potrebbe non essere finita

Oscar Health Inc

Wells Fargo analyst Elyse Greenspan maintains Aflac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>) with a Equal-Weight and raises the price target from $103 to $105.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Aflac, Raises Price Target to $105

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Ready Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RC#NYSE">RC</a>) with a Underperform and raises the price target from $3.75 to $4.25.

Keefe, Bruyette & Woods Maintains Underperform on Ready Capital, Raises Price Target to $4.25

Wells Fargo analyst Elyse Greenspan maintains Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) with a Overweight and lowers the price target from $387 to $369.

Wells Fargo Maintains Overweight on Willis Towers Watson, Lowers Price Target to $369

WIIM

PTHS

Pelthos Therapeutics shares are trading higher after the company announced the launch of ZELSUVMI topical gel for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older.

Keefe, Bruyette &amp; Woods analyst George Bose maintains PennyMac Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) with a Outperform and raises the price target from $114 to $121.

PFSI

Keefe, Bruyette & Woods Maintains Outperform on PennyMac Financial Servs, Raises Price Target to $121

Wells Fargo analyst Elyse Greenspan maintains Baldwin Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWIN#NASDAQ">BWIN</a>) with a Underweight and raises the price target from $34 to $36.

BWIN

Wells Fargo Maintains Underweight on Baldwin Insurance, Raises Price Target to $36

Wells Fargo analyst Elyse Greenspan maintains Ryan Specialty Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>) with a Equal-Weight and lowers the price target from $65 to $63.

RYAN

Wells Fargo Maintains Equal-Weight on Ryan Specialty Hldgs, Lowers Price Target to $63

Keefe, Bruyette &amp; Woods analyst Bose George maintains AG Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) with a Market Perform and raises the price target from $8.25 to $8.5.

MITT

Keefe, Bruyette & Woods Maintains Market Perform on AG Mortgage IT, Raises Price Target to $8.5

Shares of Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) have soared more than 1000% over the past three months on promising results and breakthrough hopes. Klotho stock was in the spotlight again Thursday after announcing an FDA nod on its ALS <a href="https://www.benzinga.com/markets/penny-stocks/25/06/46171467/this-penny-stock-exploded-500-in-june-what-you-need-to-know">treatment candidate.&nbsp;</a>
<h2 class="wp-block-heading">What's Driving The Rally:&nbsp;</h2>
Klotho announced<a href="https://www.benzinga.com/pressreleases/25/07/n46337387/klotho-neurosciences-inc-granted-fda-orphan-drug-designation-for-klto-202-for-treatment-of-amyotro"> it has received </a>FDA Orphan Drug Designation for its ALS therapy candidate. The official designation unlocks seven years of market exclusivity, tax credits and regulatory assistance as the potential treatment moves through the approval process.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/politics/25/07/46308025/get-ready-for-800-hours-of-blackouts-trumps-doe-warns?utm_source=articleShare">Get Ready For 800 Hours Of Blackouts, Trump&#8217;s DOE Warns</a>&nbsp;
"After the FDA&#8217;s review of the data leading to the Orphan Drug Designation, we believe this ODD designation provides strong validation of our science and our approach to treat this disease,&#8221; said Dr. Joseph Sinkule, Klotho&#8217;s CEO.
Klotho was trading at $1.50 earlier Thursday, which marks a stunning gain of 1,222% from the stock&#8217;s year-to-date low of 11 cents, reached on April 4.&nbsp;
The FDA's orphan drug designation adds to other milestones that have propelled the stock on a wild ride in 2025.&nbsp;
Last month, Klotho <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45841366/klotho-neurosciences-klto-stock-surges-over-680-whats-going-on">announced</a> positive results from a preclinical trial that showed enhancing Klotho gene expression could significantly reduce age-related organ decline and extend lifespan in animal models.&nbsp;
The company <a href="https://www.benzinga.com/markets/penny-stocks/25/06/46171467/this-penny-stock-exploded-500-in-june-what-you-need-to-know">also raised more</a> than $11 million in June through the exercise of existing warrants and eliminated all outstanding debt, resulting in a debt-free balance sheet.
<h2 class="wp-block-heading">Will the Rally Last?</h2>
The stock has seen wild swings and much of the rally is driven by retail enthusiasm, not by revenue or profit growth. Analyst coverage is minimal, and there are no reliable earnings forecasts.
Klotho also faces a potential Nasdaq delisting if it cannot&nbsp; maintain its minimum bid price by August 2025, adding another layer of risk.
<h2 class="wp-block-heading">The Bottom Line</h2>
Klotho stock is on a biotech rollercoaster—soaring on breakthrough hopes, but with volatility and uncertainty sky-high. The rally could continue if clinical progress holds, but investors should brace for sharp twists and turns ahead.&nbsp;
KLTO Stock Price Action: Klotho shares were up 5.8% at $1.44 at the time of publication Thursday, according to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46326465/unitedhealth-slammed-with-another-lawsuit-over-119-billion-stock-plunge?utm_source=articleShare">UnitedHealth Slammed With Another Lawsuit Over $119 Billion Stock Plunge</a></li>
</ul>
Photo: Shutterstock

Biotech

Small Cap

Movers

Trading Ideas

General

KLTO

Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble?

During Conference Call, Delta Exec Reportedly Says Outlook Reflects Stable Demand Across Both Consumer & Corporate Segments With Midpoint Similar To Q2 Performance

Wells Fargo analyst Elyse Greenspan maintains Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) with a Equal-Weight and raises the price target from $228 to $229.

Wells Fargo Maintains Equal-Weight on Marsh & McLennan Cos, Raises Price Target to $229

Keefe, Bruyette &amp; Woods analyst Bose George downgrades MFA Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFA#NYSE">MFA</a>) from Outperform to Market Perform and lowers the price target from $12 to $10.

Downgrades

Keefe, Bruyette & Woods Downgrades MFA Finl to Market Perform, Lowers Price Target to $10

<a href="https://www.youtube.com/watch?v=K0UwLfevw24">https://www.youtube.com/watch?v=K0UwLfevw24</a>

Macro Notification

Politics

Economics

Fed's Musalem Says So Far It Appears That Reserves Remain Abundant, There Will Be Signals If Reserves Become More Scarce; If The Fed Could Not Pay Interest On Reserves If Could Be Disruptive; Not Paying Intereset On Reserves Would Require More Active Open Market Operations To Control Liquidity; Paying Interest On Reserves Allows The Fed To Inject Liquidity If Needed Without Sacrificing Interest Rate Control

Wells Fargo analyst Elyse Greenspan maintains Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) with a Overweight and raises the price target from $436 to $438.

Wells Fargo Maintains Overweight on Aon, Raises Price Target to $438

Wells Fargo analyst Elyse Greenspan maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Equal-Weight and raises the price target from $70 to $71.

Wells Fargo Maintains Equal-Weight on WR Berkley, Raises Price Target to $71

During Conference Call, Delta Exec Reportedly Says Premium Drives Continued Margin Expansion; No Signs Of Diminishing Demand In Forward Bookings For Premium Cabins Or Services

Wells Fargo analyst Elyse Greenspan maintains Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) with a Equal-Weight and raises the price target from $260 to $264.

Wells Fargo Maintains Equal-Weight on Travelers Companies, Raises Price Target to $264

INMD

INMD stock has given up its prior loss. InMode shares were trading lower after the company cut its 2025 outlook.

Wells Fargo analyst Elyse Greenspan maintains The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Overweight and raises the price target from $134 to $138.

Wells Fargo Maintains Overweight on The Hartford Insurance Gr, Raises Price Target to $138

Wells Fargo analyst Elyse Greenspan maintains Hamilton Insurance Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>) with a Overweight and lowers the price target from $25 to $24.

Comments

Oscar Health

Notizie

Ultime notizie per Oscar Health (NYSE:OSCR) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO